The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and ...

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...

The FDA is weighing a decision that could stop compounding pharmacies from legally making cheaper versions of Mounjaro and ...

The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling medicines while it reevaluates its recent decision to declare the drugs back in ...

Facing a lawsuit, the Food and Drug Administration has decided to reconsider its decision to take popular weight-loss and diabetes drugs off of the national shortage list, which will allow compounding ...

Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...

The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...